MAESTRA 3: Phase 3 Study of INCB123667 Plus Bevacizumab Versus Bevacizumab Alone as First-Line Maintenance Therapy in Ovarian Cancer Overexpressing Cyclin E1 (clinicaltrials.gov) - Sep 2, 2026 - P3 | N=590 | Not yet recruiting | Sponsor: Incyte Corporation
New P3 trial • Fallopian Tube Cancer • Oncology • Ovarian Cancer • Peritoneal Cancer • Solid Tumor • BRCA • CCNE1
|